Cardiology 2013 (Full reference info)

Reference Type: Journal Article
Record Number: 505Author: Erlinge, D.
Year: 2013
Title: The Swedish Society of Cardiology
Journal: Eur Heart J
Volume: 34
Issue: 30
Pages: 2336
Date: Aug
Short Title: The Swedish Society of Cardiology
Alternate Journal: European heart journal
ISSN: 1522-9645 (Electronic)
0195-668X (Linking)
Accession Number: 24083306
Abstract: Dr David Erlinge, the Society President, outlines the history and present-day activities of the Society.
Notes: Erlinge, David
eng
News
England
2013/10/02 06:00
Eur Heart J. 2013 Aug;34(30):2336.
URL: http://www.ncbi.nlm.nih.gov/pubmed/24083306

Reference Type: Journal Article
Record Number: 765Author: Eschenhagen, T. and Blankenberg, S.
Year: 2013
Title: [Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases]
Journal: Internist (Berl)
Volume: 54
Issue: 2
Pages: 147-8, 150-2, 154
Date: Feb
Short Title: [Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases]
Alternate Journal: Der Internist
ISSN: 1432-1289 (Electronic)
0020-9554 (Linking)
DOI: 10.1007/s00108-012-3157-8
Original Publication: Personalisierte Therapie in der Kardiologie. Biomarker, Pharmakogenetik und Therapie monogener Erkrankungen.
Accession Number: 23371262
Keywords: Biological Markers/analysis
Cardiology/*trends
*Cardiovascular Diseases/diagnosis/genetics/therapy
Genetic Markers/*genetics
Genetic Testing/*methods
Genetic Therapy/*trends
Humans
Individualized Medicine/*methods
Molecular Targeted Therapy/*trends
Pharmacogenetics/trends
Abstract: Improved therapy and prophylaxis of cardiovascular diseases have contributed to an increase in life expectancy like no other field of medicine. However, many cardiological diseases remain untreatable and standard therapies often work only in a minority of patients or cause more harm than benefit. Personalized approaches appear to be a promising solution. Monogenic heart diseases are paradigmatic for this approach and can in rare cases be treated mutation specifically. Overall, however, success remains limited. Next generation sequencing will facilitate the identification of mutations causing diseases. Cell culture models based on induced pluripotent stem cells open the perspective of individualized testing of disease severity and pharmacological or genetic therapy. In contrast to monogenic diseases genetic testing plays no practical role yet in the management of multifactorial cardiovascular diseases. Biomarkers can identify individuals with increased cardiovascular risk. Furthermore, biomarker-guided therapy represents an attractive option with troponin-guided therapy of acute coronary syndromes as a successful example. Individual responses to drugs vary and are partly determined by genes. Simple genetic analyses can improve response prediction and minimize side effects in cases such as warfarin and high doses of simvastatin. Taken together personalized approaches will gain importance in the cardiovascular field but this requires the development of better methods and research that quantifies the true value of the new knowledge.
Notes: Eschenhagen, T
Blankenberg, S
ger
English Abstract
Germany
2013/02/02 06:00
Internist (Berl). 2013 Feb;54(2):147-8, 150-2, 154. doi: 10.1007/s00108-012-3157-8.
URL: http://www.ncbi.nlm.nih.gov/pubmed/23371262
Author Address: Institut fur Experimentelle Pharmakologie und Toxikologie, Universitatsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg. t.eschenhagen@uke.de.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155